Table 2a.
Patient ID | Submitted Phenotype | Presumed genotype | Gene | cDNA variant | Protein variant | ACMG Class | Proposed inheritance | Proposed phenotype |
---|---|---|---|---|---|---|---|---|
070617 | STGD | Heterozgous | BEST1 | c.605G > A | p.(Arg202Gln) | 4 | AD | VMD |
070682* | RP | Heterozgous | BEST1 | c.1067G > T | p.(Glu424*) | 4 | AD | VMD |
070583* | STGD | Heterozgous | CRX | c.122G > C | p.(Arg41Pro) | 4 | AD | CD/CRD |
070657 | STGD | Heterozgous | CRX | c.122G >;C | p.(Arg41Pro) | 4 | AD | CD/CRD |
070567 | STGD | Heterozgous | CRX | c.660del | p.(Tyr221Thrfs*9) | 4 | AD | CD/CRD |
070520 | STGD | Heterozgous | GUCA1A | c.250C > T | p.(Leu84Phe) | 4 | AD | CD/CRD |
070924 | STGD | Heterozgous | GUCA1A | c.296A > G | p.(Tyr99Cys) | 5 | AD | CD/CRD |
070944 | STGD | Heterozgous | PROM1 | c.1117C > T | p.(Arg373Cys) | 5 | AD | CD/CRD |
070553 | STGD | Heterozgous | PRPH2 | c.469G > T | p.(Asp157Tyr) | 4 | AD | STGD |
070509 | STGD | Heterozgous | PRPH2 | c.605G > A | p.(Gly202Glu) | 5 | AD | STGD |
070594 | STGD | Heterozgous | ROM1 | c.320del | p.(Gly107Alafs*15) | 4 | AD | RP |
070604 | STGD | Heterozgous | ROM1 | c.339dup | p.(Leu114Alafs*18) | 4 | AD | RP |
070227* | STGD | Heterozgous | ROM1 | c.668G > A | p.(Arg223Gln) | 3 | AD | RP |
070716 | STGD | Heterozgous | RP1 | c.2953_2956del | p.(Asn985Tyrfs*27) | 5 | AD | RP |
070227* | STGD | Hemizygous | CACNA1F | c.3181G > C | p.(Val1061Leu) | 3 | XL | CD/CRD |
070649 | STGD | Hemizygous | RPGR | c.2980G > T | p.(Glu994*) | 4 | XL | MD/CD/CRD |
067268 | STGD | Hemizygous | RPGR | c.3163_3164del | p.(Asn1055Glnfs*23) | 4 | XL | MD |
067202 | STGD | Hemizygous | RPGR | c.3338del | p.(Gly1113Glufs*18) | 4 | XL | CD/CRD/MD |
Note: Probands with two possible genetic explanations for disease are highlighed with an asterisk (*).
Inheritance abbreviations: AD, autosomal dominant; AR, autosomal recessive; XL, X‐linked. Phenotype abbreviations: ACMG Class., American College of Medical Genetics Classification (class 3 = variant of uncertain significance, class 4 = likely pathogenic, class 5 = pathogenic); CD, cone dystrophy; CRD, cone‐rod dystrophy; MD, macular degeneration; RP, retinitis pigmentosa; STGD, Stargardt disease; STGD1, ABCA4‐associated Stargardt disease; VMD, vitelliform macular dystrophy.